Normality S-W | Homogeneity Levene Test | ANOVA/Kruskall W | ||||
---|---|---|---|---|---|---|
Severity | Average ± SD [Min-Max] | p-value | p-value | F | p-value | |
IOP | Control (N = 38) | 15.1 ± 2.1 [10–19] | 0.222 | 0.22 | 0.73 | 0.48* |
Mild-Moderate (N = 29) | 15.6 ± 2.6 [11–22] | 0.138 | ||||
Severe (N = 34) | 15.8 ± 3 [10–21] | 0.135 | ||||
Average RNFL | Control (N = 38) | 98.6 ± 10.9 [68.9–117.5] | 0.617 | 0.78 | 2.13 | 0.12* |
Mild-Moderate (N = 29) | 101.8 ± 10.4 [82.2–125.3] | 0.651 | ||||
Severe (N = 34) | 96.3 ± 10.1 [76–118] | 0.684 | ||||
RNFL superior quadrant | Control (N = 38) | 119.9 ± 19.3 [69–159] | 0.914 | 0.13 | 0.58 | 0.56* |
Mild-Moderate (N = 29) | 124.5 ± 13.6 [85–160] | 0.215 | ||||
Severe (N = 34) | 122 ± 18.4 [90–162] | 0.695 | ||||
RNFL nasal quadrant | Control (N = 38) | 80.1 ± 16.9 [52–126] | 0.126 | 0.21 | / | 0.029 † |
Mild-Moderate (N = 29) | 79.0 ± 17.0 [47–117] | 0.533 | ||||
Severe (N = 34) | 71.3 ± 14.1 [49–115] | 0.05 | ||||
RNFL inferior quadrant | Control (N = 38) | 124.2 ± 13.7 [93–160] | 0.829 | 0.07 | 1.92 | 0.15* |
Mild-Moderate (N = 29) | 128.1 ± 19.9 [91–166] | 0.688 | ||||
Severe (N = 34) | 120.2 ± 13.9 [92–163] | 0.398 | ||||
RNFL temporal quadrant | Control (N = 38) | 70.2 ± 12.3 [47–93] | 0.410 | 0.91 | 1.34 | 0.27* |
Mild-Moderate (N = 29) | 75.3 ± 12.6 [51–101] | 0.910 | ||||
Severe (N = 34) | 71.6 ± 13.5 [45–100] | 0.272 |